Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Skip to article
Contents · Peripheral SpA
Professional Essentials · English

Professional Essentials

Five decisions for peripheral / undifferentiated SpA: phenotype, disease context, diagnostic certainty, treatment and longitudinal reassessment.

Open accessEvidence reviewed:
On this page

Peripheral / undifferentiated SpA is a clinical decision problem before it is a drug-selection problem. Peripheral SpA describes predominant arthritis, enthesitis or dactylitis within the SpA spectrum. Undifferentiated SpA describes an incompletely specified or historically labeled disease context; it is not automatically early disease, mild disease or an unconfirmed suspicion. This overview organizes assessment around five decisions.

1. Is the inflammatory peripheral phenotype credible?

Identify the structure involved. Synovitis, insertional inflammation, tenosynovitis and diffuse digit swelling are not interchangeable. Document swollen joints, the distribution of enthesis symptoms, dactylitis and functional impact. Lower-limb asymmetry may support a familiar pattern, but it is neither required nor sufficient. A convincing examination can coexist with normal serum inflammatory markers.

Separate inflammatory findings from mechanical load, structural damage and nociplastic pain. Tenderness at an enthesis is not in itself proof of inflammatory enthesitis. Ultrasound or other imaging can clarify a focused question, but an imaging abnormality also requires clinical context. Avoid turning every enthesophyte, tendon signal change or incidental HLA-B27 result into a diagnostic shortcut.

An acutely hot swollen joint requires consideration of infection and crystals before routine flare treatment. A painful red photophobic eye or visual change requires urgent ophthalmic assessment. These problems take precedence over scoring or classification. Continue with phenotyping, mimics and imaging.

2. Is there a named disease context?

Ask about personal and family psoriasis, subtle scalp or nail disease, bowel symptoms and established IBD, recurrent uveitis, relevant preceding infection and inflammatory axial symptoms. Childhood-onset disease requires review of the original phenotype and treatment history. Do not assume that an old label captures the current adult presentation.

Psoriasis may redirect the formulation toward PsA; established bowel disease toward IBD-associated SpA; a credible infectious chronology toward reactive arthritis. Axial-predominant disease belongs in the appropriate axSpA pathway. Peripheral manifestations can still be important in each condition. The purpose of redirection is to use the most applicable clinical and evidence framework, not to force mutually exclusive categories. See epidemiology and clinical heterogeneity for the population context.

If no named context is established, describe that uncertainty precisely. A working hypothesis of SpA is different from established peripheral SpA without a more specific association. See diagnostic boundaries, diagnostic evolution and juvenile-onset disease entering adult care.

3. How certain is the diagnosis?

Clinical diagnosis integrates chronology, examination, context, tests and alternatives. Classification criteria select research populations; they do not replace that synthesis. The 2011 ASAS peripheral criteria provide a framework for appropriately selected peripheral presentations. [1] Revised axial criteria should not be repurposed as a diagnostic algorithm for peripheral disease.

Order tests for a decision. Inflammatory markers help characterize burden and trends; HLA-B27 changes probability in context; RF and anti-CCP may help investigate an alternative phenotype. Synovial fluid analysis can be essential when infection or crystal disease is possible. Baseline safety testing answers a different question from diagnostic testing.

Write a formulation that can be revisited: confirmed synovitis with SpA features and no current named association, versus uncertain entheseal pain under evaluation. State what new information would strengthen or weaken it. Treatment response can inform follow-up but does not independently prove the diagnosis. Read diagnosis and classification and testing that changes management.

4. What determines treatment?

Treat the active domains and their impact. Limited non-progressive monoarthritis may permit local therapy; persistent peripheral arthritis may justify a conventional DMARD. [2] NSAID suitability depends on gastrointestinal, kidney, cardiovascular, reproductive and bowel-disease considerations. Rehabilitation should address the affected foot, hand, joint or tendon and the activity the person needs to regain.

Conventional-DMARD evidence is strongest in the peripheral arthritis context and often comes from mixed historical SpA or PsA populations. Do not infer efficacy for predominant axial disease or isolated enthesitis from a peripheral synovitis strategy. Escalation should follow documented inflammatory activity, function, response and safety rather than a pain score alone.

TNF inhibition has direct selected nonpsoriatic pSpA evidence from ABILITY-2. [3] Early-disease studies ask additional questions. SPARTACUS supplies a randomized strategy comparison in mixed early pSpA, with substantial psoriasis representation and congress-level reporting as of this review. [4] Its design strength and publication maturity are separate attributes.

For therapies beyond TNF, distinguish small direct peripheral studies from PsA-derived evidence and mechanistic rationale. The 2026 United States deucravacitinib label now includes adult PsA, but this does not establish a generic nonpsoriatic pSpA indication. [6] New approvals must be integrated without erasing the population boundary.

Organ domains can change the preferred agent. Skin, bowel, eye and axial disease need their own evidence and coordination. GRAPPA provides a useful PsA domain framework, with explicit extrapolation when applied to nonpsoriatic disease. [5] Separate four questions: efficacy, guideline recommendation, regulatory indication and practical availability. Continue to initial management, conventional DMARDs, TNF inhibition, other targeted pathways and organ-domain selection.

Pair treatment selection with safety, infection, vaccination and surgery planning and pregnancy, lactation, older age and multimorbidity review.

5. What would make you reconsider?

New psoriasis, IBD, recurrent uveitis or a clearer axial phenotype can refine the disease label. Infection, crystal arthritis, an RA pattern or a structural/mechanical problem may change the diagnosis more substantially. Ask whether disease biology changed, new information emerged or the original hypothesis no longer explains the findings.

Reassess apparent treatment failure before switching mechanisms. Confirm exposure and adherence, then compare swollen joints, entheses, function and relevant objective findings with baseline. Persistent pain can reflect ongoing inflammation, damage, mechanical load or another pain mechanism, sometimes together. Symptoms remain real even when the explanation changes.

When remission occurs, distinguish control on treatment, sustained remission and drug-free remission. Long-term CRESPA observations show that drug-free remission is possible in a subset, but a small follow-up cohort does not predict an individual outcome or authorize abrupt withdrawal. [7] Read persistent symptoms, remission and treatment reduction and long-term outcomes.

A useful follow-up record

Record the current disease formulation, diagnostic confidence, active domains, objective findings, functional priority, treatment rationale and safety plan. State the review interval, the improvement required, and the findings that would trigger escalation or diagnostic revision. One overall score cannot represent the full multidomain burden. See domain measurement and patient impact.

For each major source, keep evidence origin separate from design and publication status. A published PsA trial remains extrapolated for nonpsoriatic pSpA; a congress report can describe a strong randomized design while leaving important reporting uncertainties. Reading the evidence base, biomarkers, early intervention and future directions provide the advanced framework.

Sources

  1. Rudwaleit M et al. ASAS classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011.
  2. NICE NG65. Spondyloarthritis in over 16s: diagnosis and management — peripheral treatment recommendations.
  3. Mease P et al. Randomized controlled trial of adalimumab in nonpsoriatic peripheral spondyloarthritis: ABILITY-2. Arthritis Rheumatol. 2015.
  4. Carron P et al. SPARTACUS: 24-week results. EULAR 2026, OP0107. Ann Rheum Dis. 2026;85(Suppl 1):s91. Congress abstract.
  5. Coates LC et al. GRAPPA updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022.
  6. SOTYKTU (deucravacitinib). FDA U.S. prescribing information, revised June 2026.
  7. Damen C et al. Drug-free remission in early peripheral spondyloarthritis, including psoriatic arthritis: 10-year follow-up from CRESPA. Arthritis Rheumatol. 2026.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Peripheral SpASpondyloarthritis